An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma

Phase I: The primary objective of the Phase I portion of the study is to determine the MTD of the combination of melflufen and dexamethasone in patients with relapsed and/or relapsed-refractory multiple myeloma. Phase IIa: To evaluate the objective response rate (including minimal response [MR]) to the combination of melflufen and dexamethasone at the MTD determined in Phase I.